亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

贝伐单抗 医学 伊立替康 奥沙利铂 化疗 结直肠癌 化疗方案 内科学 养生 外科 肿瘤科 临床终点 随机对照试验 癌症
作者
Jaafar Bennouna,Javier Sastre,Dirk Arnold,Pia Österlund,Richard Greil,Eric Van Cutsem,Roger von Moos,José María Viéitez,Olivier Bouché,Christophe Borg,Claus-Christoph Steffens,Vicente Alonso-Orduña,C. Schlichting,Irmarie Reyes‐Rivera,Belguendouz Bendahmane,Thierry André,Stefan Kubicka
出处
期刊:Lancet Oncology [Elsevier]
卷期号:14 (1): 29-37 被引量:1094
标识
DOI:10.1016/s1470-2045(12)70477-1
摘要

Background Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and bevacizumab-naive second-line metastatic colorectal cancer. We assessed continued use of bevacizumab plus standard second-line chemotherapy in patients with metastatic colorectal cancer progressing after standard first-line bevacizumab-based treatment. Methods In an open-label, phase 3 study in 220 centres in Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, the Netherlands, Norway, Portugal, Saudi Arabia, Spain, Sweden, and Switzerland, patients (aged ≥18 years) with unresectable, histologically confirmed metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy were randomly assigned in a 1:1 ratio to second-line chemotherapy with or without bevacizumab 2·5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7·5 mg/kg every 3 weeks, intravenously). The choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy). A combination of a permuted block design and the Pocock and Simon minimisation algorithm was used for the randomisation. The primary endpoint was overall survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00700102. Findings Between Feb 1, 2006, and June 9, 2010, 409 (50%) patients were assigned to bevacizumab plus chemotherapy and 411 (50%) to chemotherapy alone. Median follow-up was 11·1 months (IQR 6·4–15·6) in the bevacizumab plus chemotherapy group and 9·6 months (5·4–13·9) in the chemotherapy alone group. Median overall survival was 11·2 months (95% CI 10·4–12·2) for bevacizumab plus chemotherapy and 9·8 months (8·9–10·7) for chemotherapy alone (hazard ratio 0·81, 95% CI 0·69–0·94; unstratified log-rank test p=0·0062). Grade 3–5 bleeding or haemorrhage (eight [2%] vs one [<1%]), gastrointestinal perforation (seven [2%] vs three [<1%]), and venous thromboembolisms (19 [5%] vs 12 [3%]) were more common in the bevacizumab plus chemotherapy group than in the chemotherapy alone group. The most frequently reported grade 3–5 adverse events were neutropenia (65 [16%] in the bevacizumab and chemotherapy group vs 52 [13%] in the chemotherapy alone group), diarrhoea (40 [10%] vs 34 [8%], respectively), and asthenia (23 [6%] vs 17 [4%], respectively). Treatment-related deaths were reported for four patients in the bevacizumab plus chemotherapy group and three in the chemotherapy alone group. Interpretation Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer. This approach is also being investigated in other tumour types, including metastatic breast and non-small cell lung cancers. Funding F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin应助haokeyan采纳,获得10
7秒前
Hart完成签到 ,获得积分10
14秒前
善学以致用应助风止采纳,获得10
21秒前
酷波er应助yupeijin采纳,获得10
25秒前
29秒前
33秒前
风止发布了新的文献求助10
35秒前
37秒前
没有昵称发布了新的文献求助10
40秒前
赘婿应助风止采纳,获得10
46秒前
科研通AI5应助没有昵称采纳,获得10
47秒前
48秒前
852应助顺心的星月采纳,获得10
49秒前
小pppp发布了新的文献求助10
53秒前
刘大喜发布了新的文献求助10
1分钟前
小pppp完成签到,获得积分10
1分钟前
喵喵发布了新的文献求助230
1分钟前
1分钟前
1分钟前
86400完成签到,获得积分10
1分钟前
1分钟前
香蕉觅云应助zhangyimg采纳,获得10
1分钟前
天天快乐应助Sahar采纳,获得10
1分钟前
1分钟前
1分钟前
uu发布了新的文献求助10
1分钟前
haokeyan发布了新的文献求助10
1分钟前
1分钟前
1分钟前
haokeyan完成签到,获得积分10
1分钟前
Sahar发布了新的文献求助10
1分钟前
竹子完成签到,获得积分10
1分钟前
无花果应助科研通管家采纳,获得10
1分钟前
科研通AI5应助科研通管家采纳,获得10
1分钟前
m(_._)m完成签到 ,获得积分0
1分钟前
内向耷完成签到 ,获得积分20
2分钟前
Sahar完成签到,获得积分10
2分钟前
2分钟前
2分钟前
sukii发布了新的文献求助30
2分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 610
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Virulence Mechanisms of Plant-Pathogenic Bacteria 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3561907
求助须知:如何正确求助?哪些是违规求助? 3135489
关于积分的说明 9412388
捐赠科研通 2835888
什么是DOI,文献DOI怎么找? 1558793
邀请新用户注册赠送积分活动 728452
科研通“疑难数据库(出版商)”最低求助积分说明 716832